SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
181.67
+1.41 (+0.78%)
At close: 4:00PM EDT

181.67 0.00 (0.00%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Previous Close180.26
Open181.50
Bid181.64 x 800
Ask181.66 x 1100
Day's Range179.01 - 182.25
52 Week Range79.88 - 193.56
Volume232,638
Avg. Volume408,382
Market Cap9.292B
Beta (3Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How a failed epilepsy drug became a $34,000 postpartum cure
    CNBC Videos3 months ago

    How a failed epilepsy drug became a $34,000 postpartum cure

    According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.

  • Markityesterday

    See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.

    SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding SAGE is favorable, with net inflows of $6.08 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GuruFocus.com7 days ago

    Spiros Segalas' Top 5 Buys of the 2nd Quarter

    Guru’s largest new position is Qualcomm

  • Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified?
    Simply Wall St.8 days ago

    Is Sage Therapeutics's (NASDAQ:SAGE) 287% Share Price Increase Well Justified?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...

  • Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?
    Insider Monkey27 days ago

    Is SAGE Therapeutics Inc (SAGE) A Good Stock To Buy?

    Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability […]

  • American City Business Journalslast month

    Why Sage Therapeutics' new Brier Creek center came at the perfect time

    On the same day as it cut the ribbon on its new Triangle patient support center, a Cambridge pharmaceutical company overcame the last regulation hurdle to bring its first-in-kind treatment to postpartum depression patients.

  • Life sciences VC firm Third Rock raises $770M in its largest round ever
    American City Business Journalslast month

    Life sciences VC firm Third Rock raises $770M in its largest round ever

    One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.

  • GuruFocus.com2 months ago

    Sage Therapeutics Inc (SAGE) President & CEO Jeffrey M Jonas Sold $15 million of Shares

    President & CEO of Sage Therapeutics Inc (NASDAQ:SAGE) Jeffrey M Jonas sold 85,736 shares of SAGE on 05/29/2019 at an average price of $174.78 a share.

  • Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?
    Simply Wall St.2 months ago

    Are Investors Undervaluing Sage Therapeutics, Inc. (NASDAQ:SAGE) By 29%?

    How far off is Sage Therapeutics, Inc. (NASDAQ:SAGE) from its intrinsic value? Using the most recent financial data...

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks2 months ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 SAGE Therapeutics Inc Earnings Call

  • American City Business Journals2 months ago

    New England Venture Capital Association names 2019 NEVY Awards winners

    The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.

  • Small-Cap Stocks to Watch in May
    Motley Fool2 months ago

    Small-Cap Stocks to Watch in May

    These two companies are set to announce important business updates this month.

  • Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community
    CNBC3 months ago

    Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community

    In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.

  • Analysts point to potential Biogen M&A options after Alzheimer's failure
    American City Business Journals3 months ago

    Analysts point to potential Biogen M&A options after Alzheimer's failure

    Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.

  • Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?
    Insider Monkey3 months ago

    Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

  • Most Analysts Have Been Positive on Sage Therapeutics in March
    Market Realist4 months ago

    Most Analysts Have Been Positive on Sage Therapeutics in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s